Thrombosis with thrombocytopenia syndrome (TTS) is a very rare adverse event following
immunization (AEFI). The benefits of COVID-19 vaccination with a non-replicating …

1.1 Background Since March 2021, cases of thromboses associated with thrombocytopenia
have been reported in patients vaccinated with the Oxford-AstraZeneca ChAdOx1-S and …

Abstract Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disease
caused by Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). In response to …

Coronavirus disease 2019 (COVID-19) represents a global pandemic. Several vaccines
have been produced to prevent infection and/or severe sequelae associated with infection …

INTRODUCTION—Vaccination is considered the most promising approach for ending or
containing the coronavirus disease 2019 (COVID-19) pandemic. Available vaccines have …

Background: Unusual cases of thrombocytopenia and thrombosis were reported shortly after
the introduction of the COVID-19 vaccine. In most cases, symptoms started between 5 and …

Introduction To combat COVID-19, scientists all over the world have expedited the process
of vaccine development. Although interim analyses of clinical trials have demonstrated the …

The thrombotic thrombocytopenia syndrome (TTS), a complication of COVID-19 vaccines,
involves thrombosis (often cerebral venous sinus thrombosis) and thrombocytopenia with …

Marietta, Coluccio, and Luppi present a comprehensive review of the current understanding
and hypotheses on the mechanisms of vaccineinduced immune thrombotic …

Background Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe
adverse event of SARS-CoV-2 vaccination. We describe the characteristics of patients …